Search Result

Results for "

Hypercholesterolemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA Carboxylase (1) Acyltransferase (10) Akt (6) AMPK (1) Apolipoprotein (2) Apoptosis (9) Atg8/LC3 (2) ATP Citrate Lyase (1) Autophagy (4) Bcl-2 Family (3) Biochemical Assay Reagents (5) Calcium Channel (1) CETP (2) Cholinesterase (ChE) (1) Constitutive Androstane Receptor (1) CX3CR1 (2) Cytochrome P450 (3) DNA/RNA Synthesis (2) Drug Derivative (1) Drug Isomer (1) Drug Metabolite (3) Endogenous Metabolite (8) Environmental Pollutants (1) Estrogen Receptor/ERR (1) Farnesyl Transferase (7) Fungal (1) FXR (2) G protein-coupled Bile Acid Receptor 1 (1) GLP Receptor (1) GSK-3 (3) HBV (2) HCV (5) HMG Family (2) HMG-CoA Reductase (HMGCR) (12) Indoleamine 2,3-Dioxygenase (IDO) (2) Insulin Receptor (1) Isotope-Labeled Compounds (2) JNK (3) Keap1-Nrf2 (4) LDLR (6) Liposome (1) LYTACs (1) Microsomal Triglyceride Transfer Protein (MTP) (1) Mitochondrial Metabolism (2) MOFs (1) mTOR (6) NF-κB (7) NOD-like Receptor (NLR) (2) Organoid (1) P-glycoprotein (2) p38 MAPK (5) p62 (2) PCSK9 (21) Phosphatase (2) PI3K (2) PPAR (1) Pregnane X Receptor (PXR) (1) Reactive Oxygen Species (ROS) (8) Reference Standards (11) ROCK (2) SARS-CoV (1) Ser/Thr Protease (1) Small Interfering RNA (siRNA) (1) Thyroid Hormone Receptor (5) Toll-like Receptor (TLR) (1) Xanthine Oxidase (2)
By Research Areas:	Cancer (16) Cardiovascular Disease (39) Endocrinology (2) Infection (8) Inflammation/Immunology (14) Metabolic Disease (73) Neurological Disease (3)
Oligonucleotides:	Thickeners (1) Suspending Agents (1) siRNA drugs (2) Antisense Oligonucleotides (7) siRNAs (2)

106

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10358

MK-2206 dihydrochloride Maximum Cited Publications 462 Publications Verification MK-2206 (2HCl)	Bcl-2 Family Apoptosis mTOR Akt GSK-3	Cardiovascular Disease Inflammation/Immunology Cancer
MK-2206 dihydrochloride (MK-2206 2HCl) is an orally active pan-AKT inhibitor, with IC₅₀ values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 dihydrochloride inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 dihydrochloride induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 dihydrochloride causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 dihydrochloride can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia .

HY-P9930

Evolocumab 3 Publications Verification AMG 145	NF-κB Ser/Thr Protease Toll-like Receptor (TLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

HY-148673

Laroprovstat 1 Publications Verification AZD0780; PCSK9-IN-12	PCSK9	Cardiovascular Disease Metabolic Disease
Laroprovstat (AZD0780) is an orall active PCSK9 inhibitor. PCSK9-IN-12 has bind affinity for PCSK9 with a K_d value of <200 nM. Laroprovstat binds to a pocket in the PCSK9 C-terminal domain and does not affect the PCSK9-LDL receptor (LDLR) interaction. Laroprovstat inhibits lysosomal trafficking of PSCK9-LDLR complexes and prevents PCSK9-induced LDLR degradation. Laroprovstat can be used for the research of hypercholesterolemia .

HY-108232

MK-2206 Maximum Cited Publications 462 Publications Verification	Bcl-2 Family Apoptosis mTOR Akt GSK-3	Metabolic Disease Inflammation/Immunology Cancer
MK-2206 is an orally active pan-AKT inhibitor, with IC₅₀ values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia .

HY-P99187

Bococizumab PF-04950615; RN316	PCSK9	Cardiovascular Disease Metabolic Disease
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .

HY-P4153

Enlicitide chloride MK-0616 chloride	PCSK9	Cardiovascular Disease
Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC₅₀ of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders .

HY-111431

p-Cresyl sulfate Maximum Cited Publications 6 Publications Verification p-Tolyl sulfate	JNK p38 MAPK Reactive Oxygen Species (ROS)	Metabolic Disease
p-Cresyl sulfate (p-Tolyl sulfate) is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate shows antiproliferation activity. p-Cresyl sulfate increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate activates the JNK and p38 MAPK signaling pathways .

HY-134124

Glutathione ethyl ester	Reactive Oxygen Species (ROS)	Metabolic Disease
Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense .

HY-108764

Mipomersen sodium 2 Publications Verification ISIS 301012	Apolipoprotein HCV	Metabolic Disease
Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH) .

HY-P9928

Alirocumab 1 Publications Verification REGN 727; SAR 236553	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .

HY-16274

Lapaquistat acetate 1 Publications Verification TAK-475	Farnesyl Transferase	Metabolic Disease
Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway . Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research .

HY-N0513

Loganic acid	Reactive Oxygen Species (ROS) Phosphatase NF-κB Keap1-Nrf2	Metabolic Disease Inflammation/Immunology
Loganic acid is an iridoid isolated from cornelian cherry fruits. Loganic acid inhibits NF-κB signaling pathway, activates Nrf2 signaling pathway, exhibits anti-inflammatory activity. Loganic acid can modulate diet-induced atherosclerosis and redox status. Loganic acid has strong free radical scavenging activity and remarkable cyto-protective effect against heavy metal mediated toxicity. Loganic acid is orally active .

HY-114456

Ganglioside GM3 2 Publications Verification	Insulin Receptor	Metabolic Disease
Ganglioside GM3 is a precursor of a-, b-, and c-series gangliosides, interacts with transmembrane receptors such as the epidermal growth factor and insulin receptors, and regulates receptor functions by creating a specialized lipid environment. Ganglioside GM3 is synthesized by GM3 synthase and can be used for the research of hypercholesterolemia .

HY-150223

GalNAc unconjugated/naked Inclisiran 1 Publications Verification	PCSK9 Small Interfering RNA (siRNA)	Cardiovascular Disease
GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA molecule that targets hepatic PCSK9 production to reduce LDL-C levels. GalNAc unconjugated/naked Inclisiran can be used in the research of cardiovascular diseases and hypercholesterolemia .

HY-100313A

YM-53601 5 Publications Verification	Farnesyl Transferase HCV	Infection Metabolic Disease
YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC₅₀ of 79 nM. Lipid-lowering agent . YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .

HY-106539

Colesevelam hydrochloride	FXR G protein-coupled Bile Acid Receptor 1 GLP Receptor	Metabolic Disease Cancer
Colesevelam hydrochloride is an orally active bile acid sequestrant, lipid-lowering agent, and glycemic control agent. Colesevelam hydrochloride binds bile acids in the gastrointestinal tract to form nonabsorbable complexes, interrupts enterohepatic recirculation and increases fecal bile acid elimination. Colesevelam hydrochloride modulates FXR, TGR5, and Cyp7a1 activity and triggers cAMP signaling and GLP-1 release. Colesevelam hydrochloride alters hepatic lipid and glucose metabolism, suppresses hepatic glycogenolysis, reduces hepatic triglyceride and cholesterol levels, and increases LDL-C (low-density lipoprotein cholesterol) clearance. Colesevelam hydrochloride can be used for the research of type 2 diabetes mellitus, hypercholesterolemia, and alcohol-related liver disease .

HY-148647

Mipomersen 2 Publications Verification ISIS 301012 free base	Apolipoprotein HCV	Infection
Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH) .

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .

HY-W018791

Bifendate 2 Publications Verification DDB	HBV Autophagy Cytochrome P450 Atg8/LC3 p62 P-glycoprotein	Infection Cardiovascular Disease Cancer
Bifendate (DDB), extracted from Schisandrae chinensis, is an orally active anti-HBV agent against chronic hepatitis B. Bifendate inhibits ATG5-dependent autophagy and attenuates oleic acid-induced lipid accumulation with anti-oxidant properties in vitro. Bifendate can decrease alanine transaminase (ALT) level in mice. Bifendate attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Bifendate potently increases the activity of cytochrome proteins (CYPs) and reverse P-gp-mediated multi-drug resistance (MDR) .

HY-117832

Pyripyropene A 1 Publications Verification	Acyltransferase	Infection Cardiovascular Disease Inflammation/Immunology
Pyripyropene A is an orally active, potent and selective sterol O-acyltransferase 2 (SOAT2)/acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) inhibitor, with an IC₅₀ of 0.07 µM. Pyripyropene A attenuates hypercholesterolemia and atherosclerosis in vivo .

HY-148687A

SPC5001 sodium	PCSK9	Cardiovascular Disease
SPC5001 sodium is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 sodium can be used for the research of hypercholesterolemia. SPC5001 sodium sequence: 5′-TGmCTACAAAACmCmCA-3′ .

HY-143613

THR-β agonist 2	Thyroid Hormone Receptor	Metabolic Disease
THR-β agonist 2 is a potent agonist of THR-β. THR-β agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3) .

HY-W007347

1,2-Cyclohexanedione	Biochemical Assay Reagents LDLR	Cardiovascular Disease Metabolic Disease
1,2-Cyclohexanedione is an arginine modification reagent. 1,2-Cyclohexanedione interferes with the degradation of low-density lipoprotein by modifying the arginine group in apolipoprotein. 1,2-Cyclohexanedione can be used in the research of familial hypercholesterolemia .

HY-164236

C22 Glucosylceramide (d18:1/22:0)	Endogenous Metabolite	Metabolic Disease
C22 Glucosylceramide (d18:1/22:0) is a bioactive sphingolipid composed of a d18:1 sphingoid base and a 22:0 fatty acid chain. C22 Glucosylceramide (d18:1/22:0) specifically exists in Doxorubicin (HY-15142A)-sensitive cancer cells, and its circulating concentration is positively correlated with the incidence of cardiovascular events. C22 Glucosylceramide (d18:1/22:0) has been widely used in research related to cardiovascular diseases, hypercholesterolemia, metabolic syndrome, breast adenocarcinoma and other fields .

HY-A0152

D-Thyroxine D-T4	Endogenous Metabolite	Metabolic Disease
D-Thyroxine (D-T4) is an orally active thyroid hormone that inhibits the secretion of TSH. D-Thyroxine can inhibit goiter, promote metamorphosis of tadpoles and influence cholesterol metabolism. D-Thyroxine can be used for the study of hypercholesterolemia .

HY-125544

LY 295427 Agisterol	LDLR	Metabolic Disease
LY 295427 is a LDL receptor modulator and a hypocholesterolemic agent. LY 295427 derepresses the transcription of the LDLR (LDL Receptor). LY 295427 can be used for hypercholesterolemia research .

HY-100401

Pactimibe CS-505 free base	Acyltransferase	Cardiovascular Disease
Pactimibe (CS-505 free base) is a dual ACAT1/2 inhibitor with IC₅₀s of 4.9 μM and 3.0 μM, respectively. Pactimibe (CS-505 free base) inhibits ACAT with IC₅₀s of 2.0 μM, 2.7 μM, 4.7 μM in the liver, macrophages and THP-1 cells, respectively . Pactimibe (CS-505 free base) noncompetitively inhibits oleoyl-CoA with a K_i value of 5.6 μM. Moreover, Pactimibe (CS-505 free base) obviously inhibits cholesteryl ester formation with an IC₅₀ of 6.7 μM. Pactimibe (CS-505 free base) possesses anti-atherosclerotic potential with lowering plasma cholesterol activity .

HY-P99822

Recaticimab SHR-1209	PCSK9	Metabolic Disease
Recaticimab (SHR-1209) is a humanized IgG1 mAb that selectively targets PCSK9. Recaticimab reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), triglyceride (TG), and lipoprotein(a) levels. Recaticimab can be used for hyperlipidemia research .

HY-W015806

3-Pyridineacetic acid	Endogenous Metabolite	Metabolic Disease
3-Pyridineacetic acid is an orally active nicotinic acid analog. 3-Pyridineacetic acid enhances cholesterol oxidation in rat liver mitochondria. 3-Pyridineacetic acid inhibits Triton-induced hypercholesterolemia in rats. 3-Pyridineacetic acid can be used in research related to hypercholesterolemia .

HY-150151A

GalNac-siRNA negative control (21nt)	LYTACs	Cardiovascular Disease
GalNac-siRNA negative control (21nt) is the negative control form of GalNac-siRNA. GalNac-siRNA is an Asialoglycoprotein receptor (ASGPR)-targeted inhibitor conjugate. GalNac-siRNA is promising for research of hereditary transthyretin amyloidosis, acute hepatic porphyria, hemophilia and hypercholesterolemia .

HY-122439

Lovastatin acid Mevinolinic acid; MSD803	HMG-CoA Reductase (HMGCR) Drug Metabolite	Metabolic Disease
Lovastatin acid (Mevinolinic acid; MSD803), an active metabolite of Lovastatin (HY-N0504), is a potent competitive HMG-CoA reductase inhibitor with a K_i of 0.6 nM. Lovastatin acid acts as a competitive inhibitor with respect to substrate HMG-CoA, interfering cholesterol synthesis. Lovastatin acid can be used for the research of hypercholesterolemia .

HY-100401A

Pactimibe sulfate CS-505	Acyltransferase	Cardiovascular Disease
Pactimibe sulfate (CS-505) is a dual ACAT1/2 inhibitor with IC₅₀s of 4.9 μM and 3.0 μM, respectively. Pactimibe sulfate (CS-505) inhibits ACAT with IC₅₀s of 2.0 μM, 2.7 μM, 4.7 μM in the liver, macrophages and THP-1 cells, respectively . Pactimibe sulfate (CS-505) noncompetitively inhibits oleoyl-CoA with a K_i value of 5.6 μM. Moreover, Pactimibe sulfate (CS-505) obviously inhibits cholesteryl ester formation with an IC₅₀ of 6.7 μM. Pactimibe sulfate (CS-505) possesses anti-atherosclerotic potential with lowering plasma cholesterol activity .

HY-W004580

5,5'-Dicarboxy-2,2'-bipyridine	MOFs	Cardiovascular Disease
5,5'-Dicarboxy-2,2'-bipyridine is a niacin derivative, which is promising for research of hypercholesterolemia, hyperlipidemia, and cardiovascular disease .

HY-106281

Bemfivastatin PPD 10558	HMG-CoA Reductase (HMGCR)	Metabolic Disease
Bemfivastatin (PPD 10558) is an orally active HMG-CoA Reductase (HMGCR) inhibitor. Bemfivastatin enhances the activity of liver extraction and reduces blood lipid levels. Bemfivastatin can be used for research of metabolic disease, such as hypercholesterolemia .

HY-Y0308D

Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 Disodium hydrogen phosphate, meets analytical specification of Ph. Eur. BP USP FCC E339	Biochemical Assay Reagents	Endocrinology
Sodium phosphate dibasic (Disodium hydrogen phosphate), meets analytical specification of Ph. Eur. BP USP FCC E339 is an inorganic dibasic phosphate that functions as an electrolyte supplement, a buffer carrier for injectable drugs, while also exhibiting nephrotoxicity. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 induces extensive nephrotic syndrome-like changes, including systemic symptoms such as persistent proteinuria, lipemia, hypercholesterolemia, and anemia, and causes severe renal pathological alterations such as renal enlargement, glomerular calcification, podocyte injury, and tubulointerstitial lesions. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 has the ability to induce phosphate-induced nephropathy and glomerular calcification, and can be widely used in studies on nephrotic syndrome and related renal pathological mechanisms .

HY-169813

Yakuchinone B	Acyltransferase	Cardiovascular Disease
Yakuchinone B is an Acyl-CoA: cholesterol O-acyltransferase (ACAT) inhibitor with hypocholesterolemic activity, which is found in the seeds of Zingiberaceae. Yakuchinone B inhibits rat hepatic ACAT with an IC₅₀ value of 20.6 μM. Yakuchinone B is promising for research of hypercholesterolemia and atherosclerosis .

HY-P99696

Lerodalcibep LIB003	PCSK9	Cardiovascular Disease Metabolic Disease
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .

HY-P11071

PCSK9 Inhibitor, EGF-A	PCSK9	Cardiovascular Disease
PCSK9 Inhibitor, EGF-A is a PCSK9 inhibitor. PCSK9 Inhibitor, EGF-A is residues 293-334 of the EGF-A domain of the low-density lipoprotein (LDL) receptor. PCSK9 Inhibitor, EGF-A can prevent PCSK9-induced intracellular LDLR degradation. PCSK9 Inhibitor, EGF-A can be used in the study of hypercholesterolemia and premature atherosclerosis .

HY-Y0106

2,6-Dihydroxyacetophenone	mTOR Xanthine Oxidase Apoptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC₅₀ of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia .

HY-149310

Dim16	PCSK9 HMG-CoA Reductase (HMGCR)	Metabolic Disease
Dim16 is a dual PCSK9 inhibitor and HMG-CoAR inhibitor, with an IC₅₀ of 0.8 nM against human PCSK9 and an IC₅₀ of 146.8 μM against HMG-CoAR. Dim16 disrupts the PCSK9-LDLR protein-protein interaction, inhibits the catalytic activity of HMG-CoAR, enhances cellular uptake of extracellular LDL, and suppresses PCSK9-induced platelet aggregation. Dim16 can be used in research related to hypercholesterolemia .

HY-148687

SPC5001	PCSK9	Cardiovascular Disease
SPC5001 is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 can be used for the research of hypercholesterolemia. SPC5001 sequence: 5′-TGmCTACAAAACmCmCA-3′ .

HY-148626

CVI-LM001	PCSK9	Metabolic Disease
CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .

HY-N11785

Glyceollin I	Estrogen Receptor/ERR	Metabolic Disease Cancer
Glyceollin I is a selective estrogen receptor (ER) modulator with anticancer, antioxidant, and anti-inflammatory activities. Glyceollin I is promising for research of estrogen-related cancers (e.g., breast, ovarian) and metabolic disorders (e.g., hypercholesterolemia) .

HY-11088

PF-3052334	HMG-CoA Reductase (HMGCR)	Metabolic Disease
PF-3052334 is an orally active, hepatically selective HMG-CoA reductase inhibitor with an IC₅₀ of 1.9 nM. PF-3052334 inhibits cholesterol synthesis, with IC₅₀ values of 0.9 and 730 nM in hepatocytes and muscle cells, respectively. PF-3052334 can be used to study hypercholesterolemia .

HY-111431AR

p-Cresyl sulfate potassium (Standard) p-Tolyl sulfate potassium (Standard)	JNK p38 MAPK Reactive Oxygen Species (ROS) Reference Standards	Metabolic Disease
p-Cresyl sulfate (potassium) (Standard) is the analytical standard of p-Cresyl sulfate (potassium). This product is intended for research and analytical applications. p-Cresyl sulfate (p-Tolyl sulfate) potassium is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate potassium shows antiproliferation activity. p-Cresyl sulfate potassium increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate potassium induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate potassium activates the JNK and p38 MAPK signaling pathways .

HY-100313

YM-53601 free base	Farnesyl Transferase HCV	Metabolic Disease
YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC₅₀ of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .

HY-10357

MK-2206 free base	Akt mTOR Apoptosis GSK-3 Bcl-2 Family	Metabolic Disease Inflammation/Immunology Cancer
MK-2206 free base is an orally active pan-AKT inhibitor, with IC₅₀ values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 free base inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 free base induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 free base causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 free base can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia .

HY-164236S

C22 Glucosylceramide (d18:1/22:0)-d4	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
C22 Glucosylceramide (d18:1/22:0)-d₄ is deuterium labeled C22 Glucosylceramide (d18:1/22:0) (HY-164236). C22 Glucosylceramide (d18:1/22:0) is a bioactive sphingolipid composed of a d18:1 sphingoid base and a 22:0 fatty acid chain. C22 Glucosylceramide (d18:1/22:0) specifically exists in Doxorubicin (HY-15142A)-sensitive cancer cells, and its circulating concentration is positively correlated with the incidence of cardiovascular events. C22 Glucosylceramide (d18:1/22:0) has been widely used in research related to cardiovascular diseases, hypercholesterolemia, metabolic syndrome, breast adenocarcinoma and other fields .

HY-126871

Zaragozic acid D2	Farnesyl Transferase	Metabolic Disease Cancer
Zaragozic acid D2 is the inhibitor for squalene synthase and Ras farnesyl-protein transferase (Ras FPTase), with IC₅₀ of 2 nM and 100 nM, respectively. Zaragozic acid D2 is potentially ameliorating hypercholesterolemia and Ras-induced cancer .

HY-106281A

Bemfivastatin hemicalcium PPD 10558 hemicalcium	HMG-CoA Reductase (HMGCR)	Metabolic Disease
Bemfivastatin (PPD 10558) hemicalcium is an orally active HMG-CoA Reductase (HMGCR) inhibitor. Bemfivastatin hemicalcium enhances the activity of liver extraction and reduces blood lipid levels. Bemfivastatin hemicalcium can be used for research of metabolic disease, such as hypercholesterolemia .

Cat. No.	Product Name

HY-L119

Potassium Channel Compound Library

313 compounds

Potassium channels are the most widely distributed type of ion channel and are found in virtually all living organisms. There are four major classes of K channels: voltage-gated potassium channel, calcium-activated potassium channel, inwardly rectifying potassium channel and tandem pore domain potassium channel. There is growing evidence that dysfunction in potassium channels correlates with several diseases, such as chronic hypertension, diabetes, hypercholesterolemia and atherosclerosis, etc.

MCE Potassium Channel Compound Library consists of 313 potassium channel inhibitor and activators, which is a useful tool to discover drugs for cardiovascular diseases and potassium channel research.

Cat. No.	Product Name	Type

HY-Y0308D

Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339

Disodium hydrogen phosphate, meets analytical specification of Ph. Eur. BP USP FCC E339

Biochemical Assay Reagents

Sodium phosphate dibasic (Disodium hydrogen phosphate), meets analytical specification of Ph. Eur. BP USP FCC E339 is an inorganic dibasic phosphate that functions as an electrolyte supplement, a buffer carrier for injectable drugs, while also exhibiting nephrotoxicity. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 induces extensive nephrotic syndrome-like changes, including systemic symptoms such as persistent proteinuria, lipemia, hypercholesterolemia, and anemia, and causes severe renal pathological alterations such as renal enlargement, glomerular calcification, podocyte injury, and tubulointerstitial lesions. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 has the ability to induce phosphate-induced nephropathy and glomerular calcification, and can be widely used in studies on nephrotic syndrome and related renal pathological mechanisms .

Cat. No.	Product Name	Target	Research Area

HY-P4153

Enlicitide chloride MK-0616 chloride	PCSK9	Cardiovascular Disease
Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC₅₀ of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders .

HY-134124

Glutathione ethyl ester	Reactive Oxygen Species (ROS)	Metabolic Disease
Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense .

HY-P11071

PCSK9 Inhibitor, EGF-A	PCSK9	Cardiovascular Disease
PCSK9 Inhibitor, EGF-A is a PCSK9 inhibitor. PCSK9 Inhibitor, EGF-A is residues 293-334 of the EGF-A domain of the low-density lipoprotein (LDL) receptor. PCSK9 Inhibitor, EGF-A can prevent PCSK9-induced intracellular LDLR degradation. PCSK9 Inhibitor, EGF-A can be used in the study of hypercholesterolemia and premature atherosclerosis .

HY-P2424

Cholecystokinin-J CCK-J	Calcium Channel	Others
Cholecystokinin-J (CCK-J), a cholecystokinin, stimulates Ca ²⁺ release .

HY-P10906

Talovirtide	Biochemical Assay Reagents	Others
Talovirtide is a peptide containing L-valyl .

HY-P11455

Lipopeptide CPE4	Liposome	Others
Lipopeptide CPE4 is a PEG-modified peptide E4 [(EIAALEK) ⁴]. Lipopeptide CPE4 is capable of coiled-coil formation when attached to liposomes. Lipopeptide CPE4 triggers membrane fusion between liposomes and living cells with concomitant efficient cytosolic delivery of a variety of compounds such as fluorescent dyes Propidium Iodide (PI) (HY-D0815) and TO-PRO-3 iodide (HY-117070), and Doxorubicin (DOX) (HY-15142A). Lipopeptide CPE4 can be used for drug delivery research .

HY-P10872

P315V3	SARS-CoV	Infection
P315V3 is an pan inhibitor for coronavirus, that inhibits SARS-CoV-2 prototypePT, Delta, BA.1 and BA.4 strain with IC₅₀s of 10.9, 8.9, 8.6, and 2.7 nM. P315V3 exhibits cytotoxicity in Vero cell with CC₅₀ of 4.3 μM. P315V3 exhibits anti-infectious efficacy in mouse models .

HY-W1126955

Enlicitide (decanoate) MK-0616 (decanoate)	PCSK9	Metabolic Disease Inflammation/Immunology
Enlicitide (MK-0616) decanoate is an orally active macrocyclic peptide PCSK9 inhibitor. Enlicitide decanoate binds to PCSK9, blocks its interaction with low-density lipoprotein receptor (LDLR), and enhances hepatic clearance of LDL-C. Enlicitide decanoate reduces atherogenic lipoproteins, including non-HDL cholesterol, apolipoprotein B, and lipoprotein (a). Enlicitide decanoate is applicable to research related to hypercholesterolemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease .

HY-P11766

GALA-chol GALA-cholesterol	Biochemical Assay Reagents	Cancer
GALA-chol is a cholesterol-conjugated pH-responsive fusion peptide that can serve as a delivery adjuvant. GALA-chol enhances the endocytosis of siRNA RET/PTC1-SQ nanoparticles, inhibits cell viability, and undergoes pH-responsive charge conversion in the acidic lysosomal environment, thereby promoting lysosomal escape of small extracellular vesicle (sEV) cargo. GALA-chol anchors to the sEV membrane and maintains the structural integrity and intrinsic homing activity of sEVs. GALA-chol can be used in studies related to adjuvant delivery .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9930

Evolocumab 3 Publications Verification AMG 145	NF-κB Ser/Thr Protease Toll-like Receptor (TLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

HY-P99187

Bococizumab PF-04950615; RN316	PCSK9	Cardiovascular Disease Metabolic Disease
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .

HY-P9928

Alirocumab 1 Publications Verification REGN 727; SAR 236553	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .

HY-P99822

Recaticimab SHR-1209	PCSK9	Metabolic Disease
Recaticimab (SHR-1209) is a humanized IgG1 mAb that selectively targets PCSK9. Recaticimab reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), triglyceride (TG), and lipoprotein(a) levels. Recaticimab can be used for hyperlipidemia research .

HY-P99696

Lerodalcibep LIB003	PCSK9	Cardiovascular Disease Metabolic Disease
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .

HY-P99251

Lodelcizumab LGT209; NVP-LGT209	PCSK9	Others
Lodelcizumab is a monoclonal antibody targeting PCSK9. Lodelcizumab can be used for the research of hypercholesterolemia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-111431

p-Cresyl sulfate Maximum Cited Publications 6 Publications Verification p-Tolyl sulfate	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	JNK p38 MAPK Reactive Oxygen Species (ROS)
p-Cresyl sulfate (p-Tolyl sulfate) is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate shows antiproliferation activity. p-Cresyl sulfate increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate activates the JNK and p38 MAPK signaling pathways .

HY-N0513

Loganic acid	Cardiovascular Disease Iridoids Cornaceae Classification of Application Fields Cornus officinalis Sieb. et Zucc. Terpenoids Plants Disease Research Fields Source Classification	Reactive Oxygen Species (ROS) Phosphatase NF-κB Keap1-Nrf2
Loganic acid is an iridoid isolated from cornelian cherry fruits. Loganic acid inhibits NF-κB signaling pathway, activates Nrf2 signaling pathway, exhibits anti-inflammatory activity. Loganic acid can modulate diet-induced atherosclerosis and redox status. Loganic acid has strong free radical scavenging activity and remarkable cyto-protective effect against heavy metal mediated toxicity. Loganic acid is orally active .

HY-117832

Pyripyropene A 1 Publications Verification	Cardiovascular Disease Microorganisms Classification of Application Fields Terpenoids Sesquiterpenes Inflammation/Immunology Disease Research Fields Source Classification	Acyltransferase
Pyripyropene A is an orally active, potent and selective sterol O-acyltransferase 2 (SOAT2)/acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) inhibitor, with an IC₅₀ of 0.07 µM. Pyripyropene A attenuates hypercholesterolemia and atherosclerosis in vivo .

HY-W007347

1,2-Cyclohexanedione	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Biochemical Assay Reagents LDLR
1,2-Cyclohexanedione is an arginine modification reagent. 1,2-Cyclohexanedione interferes with the degradation of low-density lipoprotein by modifying the arginine group in apolipoprotein. 1,2-Cyclohexanedione can be used in the research of familial hypercholesterolemia .

HY-N0430

Coptisine Coptisin	Alkaloids Structural Classification Classification of Application Fields Coptis chinensis Franch. Ranunculaceae Metabolic Disease Quinoline Alkaloids Plants Disease Research Fields Source Classification	Indoleamine 2,3-Dioxygenase (IDO) NF-κB p38 MAPK PI3K Akt Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism DNA/RNA Synthesis ROCK LDLR
Coptisine is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine is a reversible, uncompetitive IDO inhibitor with a K_i of 5.8 μM and an IC₅₀ of 6.3 μM. Coptisine suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine can be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease .

HY-N0430A

Coptisine Sulfate 5 Publications Verification	Alkaloids Structural Classification Chelidonium majus Classification of Application Fields Metabolic Disease Quinoline Alkaloids Plants Disease Research Fields Papaveraceae Source Classification	Indoleamine 2,3-Dioxygenase (IDO) NF-κB p38 MAPK PI3K Akt Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism DNA/RNA Synthesis ROCK LDLR
Coptisine Sulfate is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine Sulfate is a reversible, uncompetitive IDO inhibitor with a K_i of 5.8 μM and an IC₅₀ of 6.3 μM. Coptisine Sulfate suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine Sulfate shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine Sulfate inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine Sulfate inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine Sulfate downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine Sulfate be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease .

HY-A0152

D-Thyroxine D-T4	Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
D-Thyroxine (D-T4) is an orally active thyroid hormone that inhibits the secretion of TSH. D-Thyroxine can inhibit goiter, promote metamorphosis of tadpoles and influence cholesterol metabolism. D-Thyroxine can be used for the study of hypercholesterolemia .

HY-W015806

3-Pyridineacetic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
3-Pyridineacetic acid is an orally active nicotinic acid analog. 3-Pyridineacetic acid enhances cholesterol oxidation in rat liver mitochondria. 3-Pyridineacetic acid inhibits Triton-induced hypercholesterolemia in rats. 3-Pyridineacetic acid can be used in research related to hypercholesterolemia .

HY-122439

Lovastatin acid Mevinolinic acid; MSD803	Human Gut Microbiota Metabolites Endogenous metabolite Source Classification	HMG-CoA Reductase (HMGCR) Drug Metabolite
Lovastatin acid (Mevinolinic acid; MSD803), an active metabolite of Lovastatin (HY-N0504), is a potent competitive HMG-CoA reductase inhibitor with a K_i of 0.6 nM. Lovastatin acid acts as a competitive inhibitor with respect to substrate HMG-CoA, interfering cholesterol synthesis. Lovastatin acid can be used for the research of hypercholesterolemia .

HY-169813

Yakuchinone B	Monophenols Phenols Plants Alpinia oxyphylla Miq. Source Classification Zingiberaceae	Acyltransferase
Yakuchinone B is an Acyl-CoA: cholesterol O-acyltransferase (ACAT) inhibitor with hypocholesterolemic activity, which is found in the seeds of Zingiberaceae. Yakuchinone B inhibits rat hepatic ACAT with an IC₅₀ value of 20.6 μM. Yakuchinone B is promising for research of hypercholesterolemia and atherosclerosis .

HY-Y0106

2,6-Dihydroxyacetophenone	Classification of Application Fields Ketones, Aldehydes, Acids Phenols Polyphenols Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	mTOR Xanthine Oxidase Apoptosis
2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC₅₀ of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia .

HY-N11785

Glyceollin I	Structural Classification Monophenols Leguminosae Glycine max (L.) merr Phenols Plants Source Classification	Estrogen Receptor/ERR
Glyceollin I is a selective estrogen receptor (ER) modulator with anticancer, antioxidant, and anti-inflammatory activities. Glyceollin I is promising for research of estrogen-related cancers (e.g., breast, ovarian) and metabolic disorders (e.g., hypercholesterolemia) .

HY-111431AR

p-Cresyl sulfate potassium (Standard) p-Tolyl sulfate potassium (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Endogenous metabolite Source Classification	JNK p38 MAPK Reactive Oxygen Species (ROS) Reference Standards
p-Cresyl sulfate (potassium) (Standard) is the analytical standard of p-Cresyl sulfate (potassium). This product is intended for research and analytical applications. p-Cresyl sulfate (p-Tolyl sulfate) potassium is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate potassium shows antiproliferation activity. p-Cresyl sulfate potassium increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate potassium induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate potassium activates the JNK and p38 MAPK signaling pathways .

HY-100313

YM-53601 free base	Alkaloids Carbazole Alkaloids	Farnesyl Transferase HCV
YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC₅₀ of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .

HY-126871

Zaragozic acid D2	Microorganisms Ketones, Aldehydes, Acids Source Classification	Farnesyl Transferase
Zaragozic acid D2 is the inhibitor for squalene synthase and Ras farnesyl-protein transferase (Ras FPTase), with IC₅₀ of 2 nM and 100 nM, respectively. Zaragozic acid D2 is potentially ameliorating hypercholesterolemia and Ras-induced cancer .

HY-111431R

p-Cresyl sulfate (Standard) p-Tolyl sulfate (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards JNK p38 MAPK Reactive Oxygen Species (ROS)
Platycodin D (Standard) is the analytical standard of Platycodin D. This product is intended for research and analytical applications. Platycodin D is a saponin isolated from Platycodon grandiflorus, acts as an activator of AMPKα, with anti-obesity property. WNT/β-catenin pathway mediates the anti-adipogenic effect of platycodin D .

HY-A0152R

D-Thyroxine (Standard) D-T4 (Standard)	Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
D-Thyroxine (Standard) is the analytical standard of D-Thyroxine (HY-A0152). This product is intended for research and analytical applications. D-Thyroxine (D-T4) is an orally active thyroid hormone that inhibits the secretion of TSH. D-Thyroxine can inhibit goiter, promote metamorphosis of tadpoles and influence cholesterol metabolism. D-Thyroxine can be used for the study of hypercholesterolemia .

HY-129340

AS-183	Natural Products Microorganisms Source Classification	Acyltransferase
AS-183 is an inhibitor of cholesterol acyltransferase (ACAT) (IC₅₀=0.94 µM). AS-183 also inhibits the formation of cholesterol esters in HepG2, CaCo2 and THP-1 cells with IC₅₀ values of 18.1, 25.5 and 34.5 µM, respectively. AS-183 can be used in the study of atherosclerosis and hypercholesterolemia .

HY-125324

Squalestatin 3	Natural Products Microorganisms Source Classification	Endogenous Metabolite
Squalestatin 3 is a secondary metabolite, which can be isolated from Phoma. Squalestatin 3 is an inhibitor for squalene synthase with an IC₅₀ of 6 nM .

HY-N0513R

Loganic acid (Standard)	Structural Classification Iridoids Cornaceae Cornus officinalis Sieb. et Zucc. Terpenoids Plants Source Classification	Reference Standards Reactive Oxygen Species (ROS) Phosphatase NF-κB Keap1-Nrf2
Loganic acid (Standard) is the analytical standard of Loganic acid. This product is intended for research and analytical applications. Loganic acid is an iridoid isolated from cornelian cherry fruits. Loganic acid inhibits NF-κB signaling pathway, activates Nrf2 signaling pathway, exhibits anti-inflammatory activity. Loganic acid can modulate diet-induced atherosclerosis and redox status. Loganic acid has strong free radical scavenging activity and remarkable cyto-protective effect against heavy metal mediated toxicity. Loganic acid is orally active .

HY-Y0106R

2,6-Dihydroxyacetophenone (Standard)	Structural Classification Ketones, Aldehydes, Acids Phenols Polyphenols Endogenous metabolite Source Classification	Reference Standards mTOR Xanthine Oxidase Apoptosis
2,6-Dihydroxyacetophenone (Standard) is the analytical standard of 2,6-Dihydroxyacetophenone (HY-Y0106). This product is intended for research and analytical applications. 2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC₅₀ of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia .

HY-N18304

Brutieridin	Structural Classification Flavonoids Citrus limon (L.) Burm. F. Flavonones Rutaceae Plants Source Classification	Others
Brutieridin (Compound 1) is a flavanone glycoside that can be isolated from the juice of bergamot (Citrus bergamia). Brutieridin reduces the level of NPC1L1 in intestinal epithelial cells. Brutieridin decreases cholesterol uptake by intestinal epithelial cells. Brutieridin can be used in the research of hypercholesterolemia .

HY-W015806R

3-Pyridineacetic acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
3-Pyridineacetic acid (Standard) is an analytical standard for 3-Pyridineacetic acid (HY-W015806). This product is for research and analytical applications. 3-Pyridineacetic acid is an orally active nicotinic acid analog. 3-Pyridineacetic acid enhances cholesterol oxidation in rat liver mitochondria. 3-Pyridineacetic acid inhibits Triton-induced hypercholesterolemia in rats. 3-Pyridineacetic acid can be used in research related to hypercholesterolemia.

Cat. No.	Product Name	Chemical Structure

HY-164236S

C22 Glucosylceramide (d18:1/22:0)-d4

C22 Glucosylceramide (d18:1/22:0)-d₄ is deuterium labeled C22 Glucosylceramide (d18:1/22:0) (HY-164236). C22 Glucosylceramide (d18:1/22:0) is a bioactive sphingolipid composed of a d18:1 sphingoid base and a 22:0 fatty acid chain. C22 Glucosylceramide (d18:1/22:0) specifically exists in Doxorubicin (HY-15142A)-sensitive cancer cells, and its circulating concentration is positively correlated with the incidence of cardiovascular events. C22 Glucosylceramide (d18:1/22:0) has been widely used in research related to cardiovascular diseases, hypercholesterolemia, metabolic syndrome, breast adenocarcinoma and other fields .

HY-114456S

Ganglioside GM3-d7

Ganglioside GM3-d₇ is deuterium labeled Ganglioside GM3. Ganglioside GM3 is a precursor of a-, b-, and c-series gangliosides, interacts with transmembrane receptors such as the epidermal growth factor and insulin receptors, and regulates receptor functions by creating a specialized lipid environment. Ganglioside GM3 is synthesized by GM3 synthase and can be used for the research of hypercholesterolemia .

Cat. No.	Product Name		Classification

HY-108764

Mipomersen sodium 2 Publications Verification ISIS 301012		Antisense Oligonucleotides
Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH) .

HY-150223

GalNAc unconjugated/naked Inclisiran 1 Publications Verification		siRNAs siRNA drugs
GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA molecule that targets hepatic PCSK9 production to reduce LDL-C levels. GalNAc unconjugated/naked Inclisiran can be used in the research of cardiovascular diseases and hypercholesterolemia .

HY-148647

Mipomersen 2 Publications Verification ISIS 301012 free base		Antisense Oligonucleotides
Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH) .

HY-W145516

Guar gum		Thickeners Suspending Agents
Guar gum is an orally active nonionic galactomannan polysaccharide. It is present in the endosperm of Cyamopsis tetragonolobus seeds. Guar gum reduces cholesterol levels, regulates body weight, and acts as a thickener and viscosity modifier by forming hydrogen-bonded aqueous solutions. It serves as a rate-controlling excipient in compound delivery systems, and finds applications in the food, tissue engineering, nanosensing and industrial fields .

HY-148687A

SPC5001 sodium		Antisense Oligonucleotides
SPC5001 sodium is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 sodium can be used for the research of hypercholesterolemia. SPC5001 sodium sequence: 5′-TGmCTACAAAACmCmCA-3′ .

HY-150151A

GalNac-siRNA negative control (21nt)		siRNAs siRNA drugs
GalNac-siRNA negative control (21nt) is the negative control form of GalNac-siRNA. GalNac-siRNA is an Asialoglycoprotein receptor (ASGPR)-targeted inhibitor conjugate. GalNac-siRNA is promising for research of hereditary transthyretin amyloidosis, acute hepatic porphyria, hemophilia and hypercholesterolemia .

HY-148687

SPC5001		Antisense Oligonucleotides
SPC5001 is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 can be used for the research of hypercholesterolemia. SPC5001 sequence: 5′-TGmCTACAAAACmCmCA-3′ .

HY-158825

Cepadacursen sodium CIVI007 sodium		Antisense Oligonucleotides
Cepadacursen sodium is a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. Cepadacursen sodium can be used for hypercholesterolemia research and the prevention of atherosclerotic cardiovascular disease (ASCVD).

HY-148689

SPC4061		Antisense Oligonucleotides
SPC4061 an antisense nucleotide, is a potent PCSK9 inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases .

HY-148689A

SPC4061 sodium		Antisense Oligonucleotides
SPC4061 an antisense nucleotide, sodium is a potent PCSK9 inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Hypercholesterolemia

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products